Biovie | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.98.

EBIT: As of FY2026 Q1, the actual value is USD -5.482 M.

Net Loss: The net loss for the three months ended September 30, 2025, was approximately $5.1 million, compared to a net loss of $4.2 million for the same period in 2024, representing an increase of $900,000.
Total Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were approximately $5.3 million, compared to $4.1 million for the same period in 2024, an increase of approximately $1.2 million.
Research and Development Expenses: R&D expenses were approximately $2.9 million for the three months ended September 30, 2025, an increase of approximately $946,000 from $2.0 million for the same period in 2024.
General and Administrative Expenses: General and administrative expenses were approximately $2.3 million for the three months ended September 30, 2025, compared to $2.1 million for the same period in 2024, an increase of approximately $216,000.
Other Income and Expense: Other income, net was approximately $197,000 for the three months ended September 30, 2025, compared to other expenses, net of $30,000 for the same period in 2024, a net increase in other income of approximately $227,000.

Net Cash Used in Operating Activities: Approximately $3.0 million for the three months ended September 30, 2025.
Net Cash Provided by Financing Activities: Approximately $10.5 million from capital raise activities for the three months ended September 30, 2025.
Cash and Cash Equivalents: Approximately $25.0 million as of September 30, 2025.

Grant Receivable: $179,804 as of September 30, 2025, compared to $2,104,050 as of June 30, 2025.
Intangible Assets, Net: $120,997 as of September 30, 2025, compared to $178,341 as of June 30, 2025.
Goodwill: $345,711 as of September 30, 2025, unchanged from June 30, 2025.

Core Business Focus: The company is focusing on the development and commercialization of its drug candidates for neurological and neurodegenerative disorders, and advanced liver disease. This includes ongoing clinical trials for Parkinson’s Disease, Long COVID, and Alzheimer’s Disease, as well as the development of BIV201 for liver cirrhosis.
Non-Core Business: No specific non-core business activities were mentioned in the report.
Priority: The company is prioritizing the completion of its clinical trials and the potential commercialization of its drug candidates, with a focus on securing additional financing to support these efforts.

The company expects future sources of funding to include sales of equity, obtaining loans, or other strategic transactions. There is no assurance that the company will be successful in obtaining sufficient financing on terms acceptable to the company, if at all, to fund continuing operations.